NASDAQ
Lexeo Therapeutics, Inc. (LXEO)
♥ 566 Thanks from members
Lexeo Therapeutics faces a sharp divergence between advancing cardiovascular gene therapy trials, including RMAT designation for LX2020 and initiated SUNRISE-FA 2 studies, and deeply cooling alternative data sentiment paired with downward analyst revisions.